JP2019526580A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526580A5 JP2019526580A5 JP2019512191A JP2019512191A JP2019526580A5 JP 2019526580 A5 JP2019526580 A5 JP 2019526580A5 JP 2019512191 A JP2019512191 A JP 2019512191A JP 2019512191 A JP2019512191 A JP 2019512191A JP 2019526580 A5 JP2019526580 A5 JP 2019526580A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- seq
- administered
- weeks
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims description 74
- 239000013598 vector Substances 0.000 claims description 55
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 238000011225 antiretroviral therapy Methods 0.000 claims description 20
- 230000002163 immunogen Effects 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010000807 Acute HIV infection Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 241001212582 Ancara Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383140P | 2016-09-02 | 2016-09-02 | |
| US62/383,140 | 2016-09-02 | ||
| PCT/US2017/049817 WO2018045267A1 (en) | 2016-09-02 | 2017-09-01 | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526580A JP2019526580A (ja) | 2019-09-19 |
| JP2019526580A5 true JP2019526580A5 (enExample) | 2020-10-15 |
Family
ID=59887395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512191A Pending JP2019526580A (ja) | 2016-09-02 | 2017-09-01 | 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10307477B2 (enExample) |
| EP (1) | EP3506937A1 (enExample) |
| JP (1) | JP2019526580A (enExample) |
| CN (1) | CN110494159A (enExample) |
| AU (1) | AU2017318689A1 (enExample) |
| CA (1) | CA3035759A1 (enExample) |
| WO (1) | WO2018045267A1 (enExample) |
| ZA (1) | ZA201901899B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865150T3 (es) * | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
| EP3584252B1 (en) | 2015-12-15 | 2021-08-25 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| WO2017216288A1 (en) | 2016-06-16 | 2017-12-21 | Janssen Vaccines & Prevention B.V. | Hiv vaccine formulation |
| WO2018045267A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| RS60919B1 (sr) | 2016-09-15 | 2020-11-30 | Janssen Vaccines & Prevention Bv | Trimer koji stabilizuje mutacije proteina omotača hiv |
| US11229693B2 (en) | 2017-06-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding HIV antigens, and methods of use thereof |
| AU2018304502B2 (en) | 2017-07-19 | 2022-03-31 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing HIV envelope protein mutations |
| US20190083620A1 (en) * | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| AU2020279988A1 (en) * | 2019-05-22 | 2021-12-23 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| TW202110476A (zh) * | 2019-05-22 | 2021-03-16 | 荷蘭商傑森疫苗防護公司 | 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175721A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
| WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
| US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| WO2024036217A2 (en) * | 2022-08-09 | 2024-02-15 | Fred Hutchinson Cancer Center | Immunization strategies to more naturally guide the maturation of antibodies against human immunodeficiency virus (hiv) in hiv-infected subjects |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| CA2384271A1 (en) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Stabilized soluble glycoprotein trimers |
| DK1335987T4 (en) | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
| KR101042458B1 (ko) | 2001-12-04 | 2011-06-16 | 벤처 테크놀로지스 에스디엔 비에이치디 | 플라비바이러스 ｎｓ1 서브유닛 백신 |
| BR0308783A (pt) | 2002-04-25 | 2005-01-04 | Crucell Holland Bv | Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes |
| AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| US7901690B2 (en) | 2002-12-03 | 2011-03-08 | University Of Massachusetts | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
| AU2004226345B2 (en) | 2003-03-28 | 2011-12-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | MVA virus expressing modified HIV envelope, gag, and pol genes |
| WO2005027840A2 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| EP1766097A4 (en) | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | HIV-1 NEUTRALIZING ANTIBODIES INDUCED BY A TRIMER HIV-1 HYLLGLYCOPROTEIN COMPLEX |
| WO2006020071A2 (en) | 2004-07-16 | 2006-02-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines against aids comprising cmv/r-nucleic acid constructs |
| AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| CA2656741A1 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| EP1917040A4 (en) | 2005-08-23 | 2012-12-12 | Univ California | POLYVALENT VACCINE |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| CA2655934A1 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| EP2073840A4 (en) | 2006-10-23 | 2010-10-27 | Progenics Pharm Inc | MODIFIED GP140-HOLL-POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERS, COMPLEXES, AND ITS USES |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| HUE031411T2 (en) | 2007-03-02 | 2017-07-28 | Glaxosmithkline Biologicals Sa | New Methods and Preparations |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| JP5694945B2 (ja) | 2008-11-18 | 2015-04-01 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | 細胞性免疫原性が向上した抗ウイルスワクチン |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| CN102711794B (zh) | 2010-01-04 | 2015-11-25 | Kj生物科学有限公司 | 用于疫苗和诊断学的Dps融合蛋白 |
| AU2011209175B2 (en) | 2010-01-28 | 2016-02-04 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
| EP3556396B1 (en) | 2010-08-31 | 2022-04-20 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF |
| WO2014047261A1 (en) | 2012-09-19 | 2014-03-27 | Beth Israel Deaconess Medical Center, Inc. | Viruses associated with immunodeficiency and enteropathy and methods using same |
| DK2920313T3 (da) | 2012-11-16 | 2019-09-02 | Beth Israel Deaconess Medical Ct Inc | Rekombinante adenovira og anvendelse deraf |
| CN105263506B (zh) | 2013-01-07 | 2018-03-09 | 贝丝以色列女执事医疗中心 | 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法 |
| WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| US9750801B2 (en) * | 2014-02-28 | 2017-09-05 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| ES2865150T3 (es) * | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| EP3584252B1 (en) | 2015-12-15 | 2021-08-25 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| WO2017216288A1 (en) | 2016-06-16 | 2017-12-21 | Janssen Vaccines & Prevention B.V. | Hiv vaccine formulation |
| WO2018045267A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| RS60919B1 (sr) | 2016-09-15 | 2020-11-30 | Janssen Vaccines & Prevention Bv | Trimer koji stabilizuje mutacije proteina omotača hiv |
-
2017
- 2017-09-01 WO PCT/US2017/049817 patent/WO2018045267A1/en not_active Ceased
- 2017-09-01 JP JP2019512191A patent/JP2019526580A/ja active Pending
- 2017-09-01 AU AU2017318689A patent/AU2017318689A1/en not_active Abandoned
- 2017-09-01 CA CA3035759A patent/CA3035759A1/en active Pending
- 2017-09-01 CN CN201780067261.7A patent/CN110494159A/zh active Pending
- 2017-09-01 US US15/693,650 patent/US10307477B2/en active Active
- 2017-09-01 EP EP17768310.9A patent/EP3506937A1/en not_active Ceased
-
2019
- 2019-03-27 ZA ZA2019/01899A patent/ZA201901899B/en unknown
- 2019-04-16 US US16/385,062 patent/US10525123B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526580A5 (enExample) | ||
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| Ertl et al. | Novel vaccine approaches. | |
| Hasanpourghadi et al. | COVID-19 vaccines based on adenovirus vectors | |
| JP2017515508A5 (enExample) | ||
| JP2019123734A (ja) | 免疫応答の増進を目的とする方法及び組成物 | |
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| JP2019505560A5 (enExample) | ||
| WO2020247547A1 (en) | Cancer vaccine compositions and methods for use thereof | |
| JP2016074727A5 (enExample) | ||
| CA2764903C (en) | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens | |
| WO2002068654A2 (es) | Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana | |
| US11274282B2 (en) | Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen | |
| Kaulfuß et al. | Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery | |
| JP4989224B2 (ja) | Ｄｎａワクチン組成物およびその使用方法 | |
| JP2017534284A (ja) | 最適化ＨＩＶ遺伝子を含有及び発現する遺伝的に安定な複製可能センダイ（Ｓｅｎｄａｉ）ウイルスベクター | |
| US20150359877A1 (en) | Viral Vaccine Vectors | |
| Bayer et al. | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| JP7314441B2 (ja) | 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原 | |
| CN101394868A (zh) | 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 | |
| Hanke | Vehicles for Genetic Vaccines Against Human Immunodeficiency Virus Induction of T Cell-mediated Immune Responses | |
| EP1144014B1 (en) | Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors | |
| JP7454320B2 (ja) | アジュバントとしての腫瘍溶解性ウイルス | |
| Cherenova et al. | Development of Vaccines Based on Adenoviral Vectors: a Review of Foreign Clinical Studies (Part 2) |